title: [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer].
abstract: BACKGROUND
  The REGARD and RAINBOW trials showed that ramucirumab(RAM)alone and RAM plus paclitaxel(PTX) were effective therapies for advanced gastric cancer patients previously treated with chemotherapy. In this retrospective study, we evaluated the safety and efficacy of RAM alone and PTX plus RAM in such patients.
  
  
  METHODS
  Patients who were received RAM at 8mg/kg or RAM plus PTX at 80mg/m2(on days 1, 8, and 15 of a 28-day cycle)between June 2015 and March 2016 were enrolled in this study. We compared the clinical outcome of RAM alone(RAM group, n=10)with that of RAM plus PTX(PTX+RAM group, n=13).
  
  
  RESULTS
  The RAM group contained many more patients with poor performance status or prior chemotherapy of 2 or more regimens than the PTX+RAM group. All patients in both groups received chemotherapy on an outpatient basis. One case of grade 3 or 4 hematological adverse events was found in the RAM group and 6 cases were found in the PTX+RAM group. The overall response rate was 10% in the RAM group and 30% in the PTX+RAM group. Progression-free survival was 54 days in the RAM group and 187 days in the PTX+RAM group(p=0.0374). Overall survival was 158 days in the RAM group and was not reached in the PTX+RAM group(p=0.1091).
  
  
  CONCLUSIONS
  RAM alone and RAM plus PTX can be administered safely on an outpatient basis and are beneficial for advanced gastric cancer patients previously treated with chemotherapy.
authors.affiliation: Dept. of Surgery, Sakai City Medical Center.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Makari
authors.forename: Johta
authors.initials: J
authors.lastname: Mikami
authors.forename: Shunji
authors.initials: S
authors.lastname: Kamigaki
authors.forename: Ayumi
authors.initials: A
authors.lastname: Ikejima
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Genta
authors.initials: G
authors.lastname: Sawada
authors.forename: Shin
authors.initials: S
authors.lastname: Nakahira
authors.forename: Jun
authors.initials: J
authors.lastname: Yamamura
authors.forename: Ken
authors.initials: K
authors.lastname: Nakata
authors.forename: Tameyoshi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Naoki
authors.initials: N
authors.lastname: Ikeda
authors.forename: Masaki
authors.initials: M
authors.lastname: Tsujie
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ohzato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000096662:Ramucirumab